BioSpace

How Abogen went from COVID hype to a $7.8B Novartis deal

After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.

By BioSpace

1 min read
How Abogen went from COVID hype to a $7.8B Novartis deal
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights